Ischemia, often resulting from the buildup of fatty deposits such as cholesterol within arterial walls, instigates inflammation and clot formation that restrict the delivery of oxygen-rich blood to bodily tissues. While its link to cardiovascular diseases like heart attack and stroke is well recognized, this latest investigation extends the implications of ischemia to oncologic processes. Specifically, when peripheral arteries in the legs experience restricted blood flow—a condition known as peripheral artery disease (PAD)—it can double the growth rate of breast tumors, as demonstrated in murine models.

The study utilized a novel mouse model bearing nascent breast tumors, subjecting one hind limb to temporary ischemic conditions to mimic peripheral artery disease. Researchers observed a pronounced acceleration in tumor proliferation in the mice with ischemia compared to controls with normal circulation. This finding aligns with earlier work from the same group in 2020, which identified similar tumor-promoting effects of ischemia during myocardial infarction, thereby reinforcing the notion that disrupted blood flow broadly facilitates cancer progression across different physiological settings.

Central to these pathological effects is the impact ischemia has on the immune system’s hematopoietic stem cells within the bone marrow. The bone marrow serves as the reservoir for stem cells responsible for generating all immune cell types necessary for maintaining immune surveillance against infections and neoplastic growths. However, ischemic injury was found to reprogram these stem cells in a manner comparable to accelerated aging, skewing their differentiation toward myeloid lineage cells such as monocytes, macrophages, and neutrophils.

This “myeloid bias” comes at the expense of lymphocytes, particularly T cells, which are instrumental in orchestrating potent anti-tumor immune responses. The shift creates a systemic immune environment that favors immunosuppressive cell populations. Not only are these immune cells less effective at detecting and eliminating cancer cells, but their accumulation within tumor microenvironments actively shields malignant cells from immune-mediated destruction.

Within these ischemia-affected tumors, the cellular composition revealed a surge in Ly6C^hi monocytes and M2-like macrophages characterized by F4/80^+ and MHCII^lo markers, as well as regulatory T cells. These subsets collectively generate an immune milieu permissive to cancer growth by attenuating inflammatory responses and dampening cytotoxic activities. The remodeling of the tumor’s immune landscape underscores the systemic nature of ischemia-induced immune dysfunction.

Beyond alterations in cellular proportions, ischemia induces profound molecular changes at the chromatin level. The researchers documented extensive reorganization of chromatin architecture in bone marrow immune progenitors, limiting access to genes crucial for inflammatory and anti-cancer activities. These epigenetic modifications stabilize a gene expression program that perpetuates immune tolerance towards tumors, effectively enabling cancer cells to evade immune eradication.

Such findings indicate that the effects of ischemia extend far beyond transient tissue damage, triggering long-lasting reprogramming of the hematopoietic and immune systems that mimics premature aging. This phenomenon elucidates a biological mechanism linking chronic vascular impairment with increased cancer vulnerability, suggesting that cardiovascular conditions can inadvertently foster oncogenesis.

The implications of this research are wide-ranging. It highlights the necessity of integrating vascular and metabolic health considerations into comprehensive cancer prevention and treatment strategies. For patients with peripheral artery disease, earlier cancer screening may be warranted to detect tumors before ischemia-driven immune suppression promotes aggressive growth. Additionally, therapies targeting inflammation modulation might counteract the immune skewing caused by ischemic injury.

Looking forward, the NYU Langone Health team aims to translate these insights into clinical applications by designing studies that evaluate whether existing anti-inflammatory and immune-modulating drugs can mitigate post-ischemic changes and reduce cancer progression rates. Such interventions could revolutionize treatment paradigms, especially in populations at high risk for concomitant cardiovascular and oncologic disease.

This multidisciplinary study was led by Kathryn J. Moore, PhD, and Alexandra Newman, PhD, from the Jean and David Blechman Professor of Cardiology and Postdoctoral Scholar at the Leon H. Charney Division of Cardiology, NYU Grossman School of Medicine. Their collaborative effort brought together immunology, cardiology, and oncology experts to unravel the complex crosstalk between ischemic vascular injury and immune dysfunction driving tumor growth.

Funded by prominent agencies including the American Heart Association and the National Institutes of Health, the research underscores the importance of continued exploration into the interface of cardiovascular pathology and cancer biology. As the aging population faces increasing burdens of chronic vascular diseases and cancer, understanding and interrupting these interconnections will be critical to improving patient outcomes.

In summary, this pivotal study delineates how peripheral ischemia precipitates a cascade of immune alterations, mirroring hematopoietic aging, which facilitates the rapid expansion of breast tumors. By exposing this pathophysiological link, researchers have opened new avenues for preventative strategies and therapeutics that address both vascular health and tumor immunity simultaneously.

Subject of Research: Interaction between ischemic vascular injury and immune system aging in cancer progression

Article Title: Ischemic Injury Drives Nascent Tumor Growth via Accelerated Hematopoietic Aging

News Publication Date: 19-Aug-2025

Web References:

• https://pubmed.ncbi.nlm.nih.gov/32661390/
• http://dx.doi.org/10.1016/j.jaccao.2025.05.016

References:
NYU Langone Health study, JACC CardioOncology, August 19, 2025

Keywords: Cancer, cardiovascular disorders, ischemia, peripheral artery disease, bone marrow aging, immune suppression, tumor microenvironment, hematopoietic stem cells, myeloid bias, T cells, inflammation, chromatin remodeling

Anthracyclines are fundamental in treating a variety of cancers, but their efficacy comes at a steep cost. Clinicians have long grappled with the challenge of balancing the benefits of these powerful drugs against the risk of heart-related complications. Historically, the exact mechanisms by which anthracyclines induce cardiac damage have remained poorly understood, complicating the development of effective preventative strategies. This gap in knowledge has inhibited progress in safeguarding cancer patients from the associated risks of anthracycline therapy, a situation that has persisted for decades despite ongoing research efforts.

Led by Dr. Borja Ibáñez, CNIC’s Scientific Director and a noted cardiologist, the research team embarked on a mission to unravel the complexities surrounding anthracycline-induced cardiotoxicity. By utilizing an advanced experimental model, the scientists were able to simulate the effects of anthracyclines on the heart and explore potential therapeutic interventions. The study employed innovative techniques, including magnetic resonance imaging and magnetic resonance spectroscopy, which provided invaluable insights into cardiac function and metabolism under the duress of chemotherapy.

The experiment showcased the administration of a daily dose of 20 mg of empagliflozin, a medication typically used to treat type 2 diabetes. The findings were striking: the treatment effectively preserved the contractile function of the heart in pigs subjected to anthracycline therapy. More importantly, the drug demonstrated a protective effect on the heart muscle’s metabolism, addressing one of the major pathways through which anthracyclines wreak havoc. The implications of these results shine a light on the potential of empagliflozin not just as a diabetes medication but as a multifaceted therapeutic option for patients facing cancer treatment.

At the heart of the study’s findings is the identification of the protective mechanisms attributed to empagliflozin. The research suggests that the SGLT2 inhibitor enhances the heart’s ability to metabolize ketone bodies, which subsequently supports ATP production and mitochondrial function. This metabolic shift is critical because it aids in maintaining energy supply to heart cells during the stress induced by cancer drugs. Dr. Ibáñez reiterated the transformative potential of empagliflozin’s mechanisms, stating that the drug promises to directly prevent the metabolic disruptions that contribute to cardiac injury.

The study’s primary author, Danielle Medina-Hernández, emphasized the significance of the results, noting that they highlight not only the preventive capabilities of SGLT2 inhibitors but also their relevance in the broader scope of combating drug-induced cardiac damage. She articulated that the evidence suggests empagliflozin can deter structural deterioration in cardiomyocytes – the heart’s muscle cells – thereby preventing atrophy and genetic damage that can result from chemotherapeutic interference.

As the research progresses towards clinical trials, the broader implications for patients undergoing cancer treatment become evident. The integration of SGLT2 inhibitors into therapeutic protocols could transform the landscape of oncology, allowing for enhanced safety profiles while maintaining the effectiveness of cancer therapies. The initial findings open the door for further studies that could solidify empagliflozin’s role not merely as a secondary treatment but as a cornerstone of preventive cardiology in oncology.

The financial backing for this pivotal research came from esteemed sources including the European Commission and the Spanish Ministry of Science, Innovation, and Universities. Such support illustrates the increasing recognition of the need for advanced explorations into cancer treatments that consider the overall wellbeing of patients, particularly concerning their cardiovascular health. This study emphasizes the urgency of directing attention towards the intersection of oncology and cardiology, where many patients often face a dichotomy of risks.

Furthermore, the CNIC’s commitment to pioneering research in cardiovascular health has been highlighted through its innovative approaches and the utilization of cutting-edge technology. Dr. Valentín Fuster, CNIC’s General Director, stated that the melding of advanced diagnostics with clinical applications adds substantial translational value to their research efforts. By focusing on practical applications of their findings, the CNIC continues to drive forward the integration of scientific advancements into patient care pathways.

As this research unfolds and additional trials are planned, the potential for a paradigm shift in treating patients with cancer and pre-existing cardiovascular conditions has never been more tangible. The CNIC’s findings reiterate the importance of ongoing collaboration between international partners to confront complex medical challenges head-on. As scientists and clinicians work collectively to refine this approach, the overarching goal remains: to protect and enhance the quality of life for cancer patients receiving potentially life-saving yet hazardous treatments.

In conclusion, the CNIC’s groundbreaking study paves the way for innovative strategies in mitigating the cardiotoxic effects of anthracyclines, promising brighter prospects for cancer patients. Through the lens of advanced scientific inquiry and collaborative efforts, this research not only offers hope for the future but firmly establishes empagliflozin’s role in this ongoing battle against both cancer and its often devastating cardiovascular side effects.

By shifting the focus on how to preserve cardiac function while effectively treating cancer, this research serves as a beacon of progress that emphasizes the enduring strength of medical science. As clinical trials move forward, the ultimate goal will remain centered on enhancing patient outcomes and ensuring that the promise of modern medicine is delivered in a manner that safeguards health and wellbeing.

Subject of Research: People
Article Title: SGLT2i Therapy Prevents Anthracycline-Induced Cardiotoxicity in a Large Animal Model by Preserving Myocardial Energetics
News Publication Date: 4-Feb-2025
Web References: DOI
References: N/A
Image Credits: CNIC
Keywords: Drug therapy, Drug design, Preventive medicine, Mitochondrial function, Cancer medication, Drug studies, Cancer patients.